Catalyst Wire Dossier Catalyst Wire Dossier

Relugolix combination therapy

Relugolix · Sumitomo Pharma Switzerland GmbH
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Relugolix combination therapy, covering 2026-01-08 to 2026-01-08. Get the full timeline:

Most recent: Clinical Trial Update: Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy [Phase 3]

See pricing